EANS-Adhoc: Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act) Not for distribution in the United States. Epigenomics AG Places

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/Molecular diagnostics

30.03.2010

Berlin, Germany, March 30, 2010 - Epigenomics AG (Frankfurt Prime
Standard: ECX; ISIN: DE000A0BVT96) today successfully completed the
placement of 14,697,361 new ordinary bearer shares within a rights
offering representing the entire authorized capital available. The
new shares were placed at the subscription price of EUR 2.25 per new
share resulting in gross proceeds of about EUR 33.1 million. The
rights offering started on March 15, 2010 and ended on March 29,
2010.

The subscription rate in the transaction was 46.2% equalling
6,789,613 new shares. The remaining 7,907,748 unsubscribed new
shares were sold at the subscription price to retail investors as
part of a public offering in Germany and Austria, as well as to
selected institutional investors in Germany and abroad. This
public offering was significantly oversubscribed, enabling
Epigenomics AG to place the entire number of new shares. A sizeable
portion of the unsubscribed new shares were placed with funds
managed by Abingworth LLP, London, United Kingdom, that in
addition to exercising pre-emptive rights, increased their stake
in Epigenomics AG to become the largest shareholders after the
capital increase.

ICF Kursmakler AG (Frankfurt, Germany) acted as sole lead manager
and sole underwriter.

The registration of the implementation of the capital increase
with the commercial register (Handelsregister) and the admission of
the new shares to the regulated market (regulierter Markt),
Prime Standard, of the Frankfurt Stock Exchange is expected on or
around March 31, 2010. Trading in the new shares is expected to
begin on or around April 1, 2010.

With the registration of the implementation of the capital increase
the total issued share capital of Epigenomics increases from EUR
29,394,724.00 to EUR 44,092,085.00.

Epigenomics AG intends to use the net proceeds from the offering to
finance its current operations and to build and strengthen the
marketing, sales, and distribution capacities for its products, to
support ongoing and new product development for its business in
cancer screening, diagnosis, disease progression and recurrence
monitoring, and assessment of disease prognosis and in this areas in
particular the funding of further R&D, clinical trials, regulatory
approvals and market introduction of its products that are currently
in its product pipeline as well as enhancing and strengthening
capabilities related to regulatory affairs and clinical trials,
further improvement of the DNA methylation technology, additional
in-licensing agreements and strengthening its intellectual property
portfolio, as well as for general corporate purposes.

Disclaimer

This publication is not an offer of any securities for sale or a
solicitation of an offer to purchase any securities.

This document is not an offer of securities for sale or a
solicitation of an offer to purchase securities in the United
States. The shares of Epigenomics AG (the "Shares") have not been
registered under the U.S. Securities Act of 1933, as amended (the
"Securities Act") and may not be offered or sold in the United
States unless registered under the Securities Act or pursuant to an
exemption from such registration. There will be no public offering of
the Shares in the United States and the Shares will not be
registered under the Securities Act.

This document is only being distributed to and is only directed at
(i) persons who are outside the United Kingdom or (ii) to investment
professionals falling within Article 19(5) of the Financial Services
and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order")
or (iii) high net worth entities, and other persons to whom it
may lawfully be communicated, falling within Article 49(2)(a)
to (d) of the Order (all such persons together being referred to
as "relevant persons"). The Shares are only available to, and
any invitation, offer or agreement to subscribe, purchase or
otherwise acquire such securities will be engaged in only with,
relevant persons. Any person who is not a relevant person
should not act or rely on this document or any of its contents.

This communication expressly or implicitly contains certain
forward-looking statements concerning Epigenomics AG and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual
results, financial condition, performance or achievements of
Epigenomics AG to be materially different from any future results,
performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update
any forward-looking statements contained herein as a result of new
information, future events or otherwise.

The offer in Germany and Austria was made exclusively by means of
and on the basis of a prospectus published and available free of
charge at Epigenomics AG (fax number +49 30 24345 555) and ICF
Kursmakler AG (fax number +49 69 92877- 222).

Contact:

Epigenomics AG
Dr. Achim Plum
Senior VP Corporate Development
Kleine Präsidentenstr. 1
10178 Berlin
Germany
+49 30 24345 368 (phone)
+49 30 24345 555 (fax)
achim.plum@epigenomics.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Dr. Achim Plum

Sen. VP Corporate Development

Epigenomics AG

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade